Reliable access to cancer medicines plays a vital role in patient care. As healthcare providers continue to depend on established treatments, pharmaceutical companies are working to ensure these medicines remain available. In line with this effort, Septa Pharmaceuticals Inc. has acquired CeeNU® (lomustine) from Bristol Myers Squibb Canada. The acquisition strengthens Septa’s oncology portfolio and supports the continued supply of an important chemotherapy medicine in Canada.
Septa Expands Its Oncology Business
Septa Pharmaceuticals Inc. announced that it completed the acquisition of CeeNU® (lomustine) from Bristol Myers Squibb Canada, with the transaction taking effect on June 29, 2026. The company said the acquisition marks another milestone in its strategy to expand its specialty pharmaceutical business and strengthen its oncology portfolio.
CeeNU is a prescription chemotherapy medicine that contains lomustine, an alkylating agent. Healthcare professionals use it in the treatment of certain brain tumors and Hodgkin lymphoma. By adding the medicine to its portfolio, Septa is increasing its presence in the oncology market while continuing to focus on specialty pharmaceuticals.
Company Focuses on Uninterrupted Patient Access
Following the acquisition, Septa said its priority is to ensure that patients and healthcare providers continue to have uninterrupted access to CeeNU across Canada. The company stated that it is working closely with regulatory authorities, distribution partners, and other stakeholders to support a smooth transition of the product into its operations.
Maintaining a stable supply of essential medicines remains an important part of the company’s strategy as demand for reliable cancer treatments continues.
CEO Highlights Long-Term Commitment
Commenting on the acquisition, Devinder K. Sethi, President and Chief Executive Officer of Septa Pharmaceuticals Inc., said the company is committed to supporting patients and healthcare professionals throughout the transition. He added that bringing CeeNU into Septa’s portfolio reflects the company’s ongoing commitment to delivering high-quality specialty medicines while expanding its role in oncology care.
The company also noted that the acquisition aligns with its long-term goal of building a broader portfolio of therapies that address critical healthcare needs.
Plans for Future Growth
Alongside the acquisition, Septa said it will continue exploring strategic partnerships and licensing opportunities with pharmaceutical companies. The company aims to expand access to important therapies by working with partners that are looking to commercialize innovative or established medicines in new markets.
These collaborations form part of Septa’s broader growth strategy as it continues to strengthen its position in the specialty pharmaceutical sector.
Supporting the Availability of Established Cancer Treatments
The acquisition of CeeNU represents more than a portfolio expansion for Septa Pharmaceuticals. It also supports the continued availability of a well-established chemotherapy medicine that healthcare providers have relied on for years. Rather than introducing a new treatment, the transaction ensures that responsibility for supplying CeeNU in Canada moves to a company focused on specialty medicines.
As Septa integrates the product into its operations, the company says it will continue working with healthcare partners to maintain a reliable supply while pursuing additional opportunities to expand its oncology portfolio. The acquisition reflects Septa’s ongoing commitment to supporting cancer care through dependable access to essential therapies.
